ViewRay specializes in radiation therapy. The company offers the MRIdian magnetic resonance imaging (MRI) guided adaptive radiotherapy system, a technology that provides cancer treatment by clearly defining the targeted tumor from the surrounding soft tissue and other critical organs during radiation treatment. It primarily serves the healthcare sector, particularly oncology. It was founded in 2004 and is based in Oakwood Village, Ohio. In July 2023 ViewRay filed for bankruptcy.
Expert Collections containing ViewRay
Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.
ViewRay is included in 2 Expert Collections, including Digital Health.
The digital health collection includes vendors developing software, platforms, sensor & robotic hardware, health data infrastructure, and tech-enabled services in healthcare. The list excludes pureplay pharma/biopharma, sequencing instruments, gene editing, and assistive tech.
This collection includes companies applying technology to cancer care, diagnosis, and treatment. Examples include vendors offering cancer detection and diagnosis, oncology clinical decision support, real-world data, and AI oncology drug discovery.
ViewRay has filed 75 patents.
Magnetic resonance imaging, Nuclear magnetic resonance, Radiation therapy, Medical imaging, Neuroimaging
Magnetic resonance imaging, Nuclear magnetic resonance, Radiation therapy, Medical imaging, Neuroimaging
Latest ViewRay News
Feb 14, 2024
ce-guided adaptive radiation therapy may improve overall survival in patients with pancreatic cancer Baptist Health South Florida MIAMI, FL – January 15, 2024 – A study co-led by researchers at Miami Cancer Institute, part of Baptist Health South Florida, found that ablative stereotactic magnetic resonance (MR)-guided adaptive radiation therapy may improve local control (LC) and overall survival (OS) in patients with borderline resectable (BRPC) and locally advanced pancreas cancer (LAPC). Long-term outcomes from the Phase 2 SMART trial demonstrate encouraging OS and limited toxicity as published recently in Radiotherapy & Oncology (“The Green Journal”). “Pancreatic ductal adenocarcinoma is a leading cause of cancer death. Surgery is the only known curative treatment, although most newly diagnosed patients are not surgical candidates due to locally extensive and/or distant metastatic disease,” said Michael D. Chuong, M.D., vice chair and medical director of proton therapy and photon therapy in the department of radiation oncology at Miami Cancer Institute, and senior author of the study. “Ablative radiation therapy may benefit patients with advanced pancreatic ductal adenocarcinoma by improving LC, reducing pain, and enhancing quality-of-life.” This first prospective, multi-center, single-arm open-label Phase 2 trial enrolled 136 patients at thirteen centers in three countries after ≥3 months of any chemotherapy without distant progression and a serum carbohydrate antigen (CA 19-9) tumor marker level of £500 U/mL. Stereotactic magnetic resonance (MR)-guided adaptive radiation therapy (SMART) was delivered on a 0.35T MR-guided system prescribed to 50 Gy in 5 fractions. Surgery and chemotherapy were permitted after SMART. Median OS from diagnosis and SMART was 22.8 months and 14.2 months, respectively. Two-year OS for the entire cohort from diagnosis and SMART was 53.6 % and 40.5 %, respectively, which is significantly higher than what is expected after chemotherapy +/- standard radiation therapy. Two-year estimated OS for resected vs. unresected patients from SMART was 67 % vs. 26 % respectively. Two-year LC from diagnosis and SMART for the entire cohort was 77.7 % and 78.2 %, respectively, and was higher for resected vs. unresected patients (90 % vs. 71 %; p = 0.019). “The SMART trial is the first to prospectively demonstrate the safety of delivering ablative radiation dose for advanced pancreas cancer, which resulted in excellent long-term LC even among patients who did not have surgery,” added Dr. Chuong. “We are especially excited by the potential for ablative radiation therapy to also prolong OS. A Phase 3 randomized trial evaluating whether OS is definitely improved with addition of ablative SMART to chemotherapy versus chemotherapy alone for advanced pancreas cancer is warranted,” said Dr. Chuong. About Miami Cancer Institute Miami Cancer Institute brings to South Florida access to personalized clinical treatments and comprehensive support services delivered with unparalleled compassion. No other cancer program in the region has the combination of cancer-fighting expertise and advanced technology—including the first proton therapy center in South Florida, Latin America and the Caribbean, and one of the only radiation oncology programs in the world with each of the newest radiation therapies in one place—to diagnose and deliver precise cancer treatments that achieve the best outcomes and improve the lives of cancer patients. The Institute offers an impressive roster of established community oncologists and renowned experts, clinical researchers and genomic scientists recruited from the nation’s top cancer centers. Selected as Florida’s only member of the Memorial Sloan Kettering Cancer (MSK) Alliance, Miami Cancer Institute is part of a meaningful clinical collaboration that affords patients in South Florida access to innovative treatments and ensures that the standards of care developed by their multidisciplinary disease management teams match those at MSK. For more information, please visit https://cancer.baptisthealth.net/miami-cancer-institute . Miami Cancer Institute is part of Baptist Health Cancer Care, the largest cancer program in South Florida, with locations from the Florida Keys to the Palm Beaches. ### COI Statement Corresponding author: Parag Jitendra Parikh, BSE, MD. ; E-mail:PParikh2@hfhs.orgThis research has been supported by ViewRay, Inc.This protocol is registered with ClinicalTrials.gov and may be viewedonline at https://clinicaltrials.gov/ct2/show/NCT03621644.Disclosures: P.J.P. reports research grants, consulting fees, and honoraria fromViewRay, Inc, and grants from Galera, is a stock owner for Nuvaira, and is supported by Elizabeth, Allan & Warren Shelden Fund outside of submitted work.P.L. reports personal fee from ViewRay, Inc, grants and personal fees from AstraZeneca, personal fees and nonfinancial support from Varian, and personal feesfrom Genentech, Inc, outside the submitted work. D.A.L. reports consulting fees,honoraria, and travel support from ViewRay, Inc, grants from Varian and TripletState, patents with UCLA, SAB membership for TAE Life Sciences, and leadershiproles at Jewish Sacred Music Foundation, AAPM, and American Society for Radiation Oncology. J.K. reports consulting and travel support from ViewRay, Inc, travelsupport from Varian, and honoraria from University of Washington and RoswellPark Cancer Institute. K.E.M. reports personal fees from ViewRay, Inc, is acofounder of MR Guidance LLC, and reports grants from ViewRay, Inc, outside ofsubmitted work. M.F.B. reports institutional support for clinical trial from AstraZeneca, honoraria from University of Virginia, and honoraria and travel reimbursement from University of Calgary (Edmonton Health Services). C.K.G.-H. reportsresearch funding from the National Institutes of Health (R01CA204189,R01HL153720, and R01CA236857) and research agreements with Modus MedicalDevices and GE Healthcare outside of submitted work. A.C.R. reports consultingfees from ViewRay, Inc, and grant funding from ViewRay, Inc, Joseph DrownFoundation, and Intelligent Automation, Inc, outside of submitted work. Y.Y.reports research support, honoraria, and consulting for ViewRay, Inc, outside ofsubmitted work. L.P. reports study and advisory funding from ViewRay, Inc. H.K.reports research funding and honoraria from ViewRay, Inc, and Varian. L.E.H.reports research funding from Varian, consulting fees from Varian and Radialogica, honoraria from Varian, LusoPalex, and ViewRay, Inc, and ViewRay consortium membership. A.T.P. reports speaker fees from ViewRay Technologies, Inc,and speaker and travel fees from SunNuclear Corp. C.L.W. reports prior researchgrant support and speaker honoraria from ViewRay, Inc. R.P. reports consultingfees from ViewRay, Inc, outside of the submitted work. A.C.M. reports RSNAResearch Scholar Grant, W. Kim Foster Foundation Research Grant, and researchfunding from ViewRay, Inc, outside of submitted work. M.R.P. reports boardmembership with ISCORT (Israel Society for Clinical Oncology and Radiotherapy). K.E.M. reports honoraria from ViewRay, Inc. P.K. reports research grantsupport from ViewRay, Inc, Mevion, and Varian outside of submitted work. A.P.S. reports research funding from ViewRay, Inc, Varian, and CIRS, Inc, consultingfor ViewRay, Inc, and honoraria from Varian. L.B. reports speaker honoraria andresearch and travel support from ViewRay, Inc, consulting for Varian and Medipass srl, patents with Universita Cattolica del Sacro Cuore, advisory board membership for IBA, and a leadership role with AIRO. L.P. reports research grantsupport from ViewRay, Inc. M.F. reports employment by ViewRay, Inc, and stockownership. M.D.C. reports consulting, honoraria, advisory board, research funding, and travel support from ViewRay, Inc, honoraria from Sirtex, researchfundingfrom Novocure, research funding from StratPharma, honoraria from IBA, andhonoraria from GenesisCare. No other disclosures were reported.Research data are stored in an institutional repository and will beshared upon request to the corresponding author.Acknowledgments—The authors thank Scott Dill, PhD, Aine Duffy,PhD (NAMSA, New York, NY), Teresa Yurik (NAMSA, Minneapolis,MN), and Stewart Richmond, PhD (NAMSA, Selby, United Kingdom) fortheir assistance in the preparation of this article. Disclaimer: AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the use of any information through the EurekAlert system. Media Contact
ViewRay Frequently Asked Questions (FAQ)
When was ViewRay founded?
ViewRay was founded in 2004.
Where is ViewRay's headquarters?
ViewRay's headquarters is located at 2 Thermo Fisher Way, Oakwood Village.
What is ViewRay's latest funding round?
ViewRay's latest funding round is Bankrupt/Admin.
How much did ViewRay raise?
ViewRay raised a total of $217.34M.
Who are the investors of ViewRay?
Investors of ViewRay include ViewRay Technologies, CRG, Kearny Venture Partners, OrbiMed Advisors, F-Prime Capital and 10 more.
Who are ViewRay's competitors?
Competitors of ViewRay include Monteris Medical, TNI medical, Augmenix, HyperMed Imaging, CardioInsight Technologies and 7 more.
Compare ViewRay to Competitors
Calypso Medical provides technologies in the radiation oncology market
Radiation Shield Technologies specializes in the research, design, and production of personal protection systems within the safety and defense industry. The company offers products such as full body suits, blankets, and tents made from a patented, lightweight, non-toxic, and lead-free fabric called Demron, which is designed to protect individuals from ionizing and nuclear radiation. These products are aimed at providing safety for users in environments where radiological or nuclear hazards are present. It is based in Coral Gables, Florida.
Smart Animal is a research company focused on personalized medicine within the immunotherapy and diagnostics sectors. They offer a platform-oriented device that modifies or enhances the body's immune response to target diseases, administered in outpatient settings. The company's technology is used for labeling antibodies for imaging and targeted drug delivery in cancer treatment and can be applied to autoimmune disorders and veterinary use. It was founded in 2006 and is based in Marlborough, Massachusetts.
Civatech Oncology is a medical device company focused on the development of polymer-based devices that treat cancer using localized, low-dose-rate radiation. The company's fabrication methods allow for the encapsulation of radioactive materials into polymer structures. These polymer-based brachytherapy devices offer physicians treatment options for tumors with low-dose-rate brachytherapy. CivaTech Oncology was founded in 2006 and is based in Durham, North Carolina.
InnerOptic Technology, Inc. specializes in augmented reality and image guidance systems for the medical sector. The company offers FDA-cleared 3D navigation tools designed to enhance the precision and safety of medical procedures. These products are primarily utilized in the healthcare industry to assist with interventions such as needle navigation and surgical procedures. It is based in Hillsborough, North Carolina.
HyperMed Imaging is a company focused on medical hyperspectral imaging within the healthcare industry. The company's main offering is advanced portable imaging technology that assesses oxyhemoglobin, deoxyhemoglobin, and oxyhemoglobin saturation in superficial tissue, providing key information for various healthcare applications. The primary sector HyperMed Imaging serves is the healthcare industry, specifically in areas requiring quick and efficient determination of surface tissue oxygenation. It was founded in 1997 and is based in Memphis, Tennessee.